High Throughput Screening (HTS) Market to Grow by USD 19.9 Billion (2024-2028), Boosted by Rising R&D Investments, with AI Redefining Market Landscape - Technavio

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global high throughput screening (HTS) market size is estimated to grow by USD 19.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 12.12%  during the forecast period. Rise in R and D investments is driving market growth, with a trend towards increasing focus on promotional activities. However, shortage of trained healthcare professionals  poses a challenge. Key market players include Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Technavio has announced its latest market research report titled Global High Throughput Screening (HTS) Market 2024-2028
Technavio has announced its latest market research report titled Global High Throughput Screening (HTS) Market 2024-2028

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

High Throughput Screening (HTS) Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 - 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 12.12%

Market growth 2024-2028

USD 19.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

11.64

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Japan, China, Germany, and France

Key companies profiled

Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Market Driver

High-throughput screening (HTS) is a key trend in the life sciences sector, particularly in the areas of drug discovery and research for complex illnesses like cancer and neurological disorders. HTS allows for the rapid testing of large compound libraries using automated equipment such as robotic arms and microplate readers. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to analyze genomic data and chemical databases for target identification. Biotech startups and academic institutions are driving innovation in this field, with pharmaceutical corporations and research organizations collaborating to advance drug development. HTS is also used in stem cell research, toxicology, and open innovation models. HTS service providers offer instruments, software, and consumables to support this research. HTS is transforming the biopharmaceutical industry, enabling precision medicine and the repurposing of existing drugs for new indications. With advancements in technology, HTS is becoming more accessible to a wider range of organizations, including biotechnology startups and clinical trials. Despite these advancements, challenges remain, including false-positive findings and the need for specialized equipment maintenance. Overall, HTS is a vital tool in the global healthcare sector's quest to develop new products and services for the detection and treatment of chronic diseases.